相关实验视频

Updated: May 29, 2025

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

Published on: July 31, 2021

评估库尔玛林衍生物埃斯库莱丁在患有饮食诱导肥胖症的老鼠中的抗糖尿病作用

Bian Wu¹, Junyu Wang¹, Guishun Sun¹

¹Department of General Surgery II, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Yunnan Province Clinical Research Center for Senile Diseases, Kunming, Yunnan, China.

Biotechnology and applied biochemistry

|February 4, 2025

概括

埃斯库莱丁是一种氨酸衍生物,有效地对抗老鼠的肥胖和高血糖症. 这种天然化合物可以降低体重指数 (BMI) 和血糖,为代谢障碍提供有前途的治疗方法.

科学领域:

药理学药理学是指药理学的学科.
生物化学生物化学
内分泌学在内分泌学.

背景情况:

肥胖是一种与久坐不动的生活方式和非传染性疾病相关的全球健康威胁.
肥胖和2型糖尿病共享复杂的致病途径.
目前的抗肥胖和抗糖尿病药物可能会在长期使用时引起不良反应.

研究的目的:

为了研究aesculetin的抗肥胖和抗糖尿病潜力,一种氨酸衍生物.
为了评估aesculetin对体重指数 (BMI),血糖控制和肥胖,高血糖大鼠的脂质概况的影响.
评估骨对器官功能,心脏组织和炎症/抗氧化剂标记物的影响.

主要方法:

在使用高脂肪饮食和链毒素的老鼠中诱导肥胖和高血糖症.
鼠被用骨治疗,并评估了各种生理和生化参数.
关键评估包括BMI,HbA1c,脂质样本,和肝功能标志物,以及心脏组织的组织病理分析.

主要成果:

埃斯库林显著降低了BMI,HbA1c和胆固醇水平,同时增加了肥胖糖尿病大鼠的胰岛素分泌.
该化合物对和肝功能产生保护作用,并预防心脏组织损伤.
素调节了阿迪波金,增强了抗氧化活性,并减少了促炎性细胞因子.

结论:

埃斯库莱丁具有显著的抗肥胖和抗糖尿病特性.
这些发现表明,骨可以改善肥胖引起的高血糖和相关并发症.
埃斯库林是治疗代谢障碍的潜在治疗剂.

关键词:

一个小小的骨架.有高脂肪的饮食.过高血糖症 (hyperglycemia) 是一种在体内研究研究体内研究.肥胖肥胖肥胖肥胖肥胖肥胖肥胖肥胖植物化学品植物化学品

更多相关视频

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

相关概念视频

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...